home / stock / aura / aura news

AURA News and Press, Aura Biosciences Inc. From 06/30/22

Stock Information
Company Name: Aura Biosciences Inc.
Stock Symbol: AURA
Market: NASDAQ
Website: aurabiosciences.com
Menu
AURA AURA Quote AURA Short AURA News AURA Articles AURA Message Board
Get AURA Alerts

News, Short Squeeze, Breakout and More Instantly...
AURA - Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ...
AURA - Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma

In this Retrospective Matched Case Control Study, Belzupacap Sarotalocan Achieved Statistically Significant Vision Preservation Compared to Plaque Radiotherapy, the Current Standard of Care Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developi...

AURA - Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced multiple presentations of data evaluating its first VDC, belzupacap sarotalocan (AU-011),...

AURA - Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the publication of preclinical data on AU-011, its first VDC product candidate, in combin...
AURA - Aura Biosciences to Participate in Upcoming Investor Conferences

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that members of its executive team will participate in the following upcoming investor co...

AURA - Aura Biosciences GAAP EPS of -$0.44 misses by $0.01

Aura Biosciences press release (NASDAQ:AURA): Q1 GAAP EPS of -$0.44 misses by $0.01. Cash and cash equivalents and marketable securities totaling $133.3 million. Aura believes its current cash and cash equivalents and marketable securities are sufficient to fund its operations into 2024. Fo...

AURA - Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

On Track to Meet Multiple Clinical Milestones for AU-011 in 2H 2022: Initiate Pivotal Trial in Choroidal Melanoma, Initiate Phase 1 Trial in Non-Muscle Invasive Bladder Cancer, and Submit IND for Choroidal Metastases Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage bio...
AURA - Aura Biosciences Presents Preclinical Data Highlighting AU-011's Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting

Preclinical studies support further development of AU-011 for choroidal metastasis Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today anno...

AURA - Aura Biosciences to Present at the 2022 Bank of America Healthcare Conference

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer of Aura will present at the 2022...

AURA - Aura Biosciences reports Q4 results

Aura Biosciences press release (NASDAQ:AURA): Q4 net loss of $11.6M As of December 31, 2021, company had cash and cash equivalents totaling $149.1M. For further details see: Aura Biosciences reports Q4 results

Previous 10 Next 10